In the clinic
Tuesday, June 10, 2014
Quest Pharmatech Inc., of Edmonton, Alberta, reported that patient enrollment has been completed in the company's phase IIb trial of its lead immunotherapy product candidate, oregovomab, to treat ovarian cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.